Saturday, September 5, 2026
Court says Vertex Casgevy fertility perk is a kickback
The US Court of Appeals for the District of Columbia Circuit on September 4, 2026 affirmed a lower-court finding that Vertex's program offering fertility-preservation services to Casgevy patients violates the federal Anti-Kickback Statute. The court said the perk was remuneration meant to induce purchase of the multimillion-dollar sickle-cell gene therapy. Bloomberg Law reported the panel stopped short of affirming a separate lower-court conclusion, leaving Vertex to recast how it supports patients through Casgevy's fertility risks.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- Vertex closes $10 billion Crinetics acquisitionWednesday, September 2, 2026
- Crinetics shareholders approve Vertex's $10 billion buyoutTuesday, September 1, 2026
- Court clears Lupin's generic Kalydeco in Vertex patent fightThursday, August 27, 2026
- Rival's cystic fibrosis drug fails, Vertex shares gainThursday, August 13, 2026